ClinicalTrials.gg
CompletedNCT03061721EVIDENCES IVUpdated Oct 24, 2024Results posted

Saroglitazar Magnesium in Patients With Nonalcoholic Fatty Liver Disease and/or Nonalcoholic Steatohepatitis

A Phase 2 interventional study of Saroglitazar magnesium 1 mg and Saroglitazar magnesium 2 mg in Non-Alcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis, sponsored by Zydus Therapeutics Inc.. Completed at 18 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-10-24.

Sponsored by Zydus Therapeutics Inc. (part of Zydus Lifesciences Limited) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States — 60 open to participants now, 93 under way, 13 of them phase 3. Non-alcoholic Fatty Liver Disease · United States.

Enrollment
156th of 460
106 · median 56
Started
2017
with 25 others
Phase 2
192 of 547
15 open now
Registered
201st of 547
by date

Among the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, this one is the 156th largest by enrollment of the 460 interventional ones that give a count, is one of 26 that started in 2017, is one of 192 in phase 2, and was the 201st registered.

Non-alcoholic Fatty Liver Disease

1,617 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

60 of the 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States are open now. Recruiting first, the newest first:

55 more — sign in →

All 60 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 547 studies in Non-alcoholic Fatty Liver Disease with a site in United States, or all of them as a file.
02

Study summary

This is a randomized, double-blind, placebo-controlled study in up to 104 patients with a diagnosis of Non-alcoholic fatty Liver disease (NAFLD) and/or Non-alcoholic steatohepatitis (NASH). The study will be conducted over a period of up to 22 weeks and will include an optional Prescreening, Screening (Days -35 to -7) Phase, a 16-week Treatment Phase following randomization on Day 1. Patients will be randomly assigned in a ratio of 1:1:1:1 to receive Saroglitazar Magnesium 1mg or 2 mg or 4 mg or matching placebo once daily in the morning before breakfast for 16 Weeks. The primary endpoint of the study is percentage change from baseline in serum Alanine transaminase (ALT) levels at Week 16 in the Saroglitazar Magnesium groups as compared to the placebo group.

03

Conditions studied

  • Non-Alcoholic Fatty Liver Disease
  • Nonalcoholic Steatohepatitis

Keywords

  • NASH
  • NAFLD
  • Saroglitazar
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males or females, 18 to 75 years of age, with (BMI) ≥ 25 kg/m\^2.
  2. Documented diagnosis of NAFLD established either by imaging (ultrasound, computed tomography [CT] scan or Magnetic resonance imaging [MRI]) or liver showing NASH or simple steatosis, within the 24 months preceding Visit 1. The diagnosis of NAFLD is made according to the American Association for the Study of Liver Diseases (AASLD) criteria (Chalasani et al. Hepatology 2012; 55:2005-2023).
  3. level of ≥50 U/L at Visit 1 and Visit 2 with ≤30% variance between the levels at Visit 1 and Visit 2.
  4. Patient's demonstration of understanding of study requirements and treatment procedures, willingness to comply with all protocol-required evaluations; provision of written before any study specific tests or procedures are performed.

Exclusion criteria

Exclusion Criteria:

  1. Consumption of > 3 units of alcohol per day (> 21 units per week) if male and > 2 units of alcohol per day (>14 units per week) if female for at least 3 consecutive months in the 5 years preceding Visit 1 (Note: 1 unit = 12 ounces of beer, 4 ounces of wine or 1 ounce of spirits/hard liquor).
  2. Presence of alternative causes of fatty liver, including:

    1. Weight change >5% within the 3 months preceding Visit 1
    2. Total parenteral nutrition, starvation or protein-calorie malnutrition within the 90 days preceding Visit 1.
    3. Use of drugs associated with NAFLD for more than 12 consecutive weeks in the 1 year before Visit 1, including amiodarone, tamoxifen, methotrexate, systemic , anabolic steroids, tetracycline, estrogens in doses higher than used in oral , vitamin A, L asparaginase, valproate, chloroquine or antiretroviral drugs
  3. Initiation of vitamin E at doses > 100 IU/day, or multivitamins containing > 100 IU/day of vitamin E in the 3 months preceding Visit 1.
  4. Use of drugs with potential effect on NASH such as ursodeoxycholic acid, S-adenosylmethionine (SAM-e), betaine, pentoxifylline, obeticholic acid or milk thistle in the 3 months prior to Visit 1.
  5. Changing doses of statins (simvastatin, pitavastatin, pravastatin, atorvastatin, fluvastatin, lovastatin, rosuvastatin) or fibrates (clofibrate, fenofibrate) in the 3 months preceding Visit 1.
  6. Use of thiazolidinediones (pioglitazone, rosiglitazone).
  7. Use of drugs that are known Cytochrome P4502C8 (CYP2C8) inhibitors/substrate
  8. History of bowel surgery (gastrointestinal (bariatric) surgery or undergoing evaluation for bariatric surgery for obesity, extensive small-bowel resection or orthotopic liver transplant (OLT) or listed for OLT.
  9. History of other chronic liver disease (chronic , (HCV) infection, irrespective of their mRNA HCV assay status or active infection, (i.e., serum positive for hepatitis B surface antigen) or hepatitis, cholestatic and metabolic liver diseases) or hemochromatosis
  10. Patient has known cirrhosis, either based on clinical criteria or liver histology.
  11. Patient with Internation Normalised Ratio () >1.3.
  12. Type 1 diabetes mellitus.
  13. Poorly controlled type 2 diabetes mellitus, i.e., glycosylated () > 9%.
  14. Unstable cardiovascular disease, including:

    1. unstable angina, (i.e., new or worsening symptoms of coronary heart disease within the 3 months preceding Visit 1), acute coronary syndrome within the 6 months preceding Visit 1, acute myocardial infarction within the 3 months preceding Visit 1 or heart failure of class (III - IV) or worsening congestive heart failure, or coronary artery intervention, within the 6 months preceding Visit 1
    2. history of (within 3 months preceding Visit 1) or current unstable cardiac dysrhythmias
    3. uncontrolled hypertension (systolic blood pressure [BP] > 160 mmHg and/or diastolic BP > 100 mmHg)
    4. stroke or within the 6 months preceding Visit 1.
  15. History of myopathies or evidence of active muscle disease.
  16. History of in the 5 years preceding Visit 1 and/or active neoplasm with the exception of resolved superficial nonmelanoma skin cancer.
  17. Any of the following laboratory values:

    1. Hemoglobin \< 9 g/dL
    2. White blood cell count \< 2.5 × 103/μL
    3. \< 1.5 × 103/μL
    4. \< 100 × 103/μL
    5. Total Serum > 1.5 mg/dL (except in patient with known Gilbert bilirubin where Total Bilirubin up to 2.5 mg/dL is allowed), if it is \<1.5 mg/dL at screening and >30% variance in the levels at Visit 1 and Visit 2
    6. Albumin \< 3.2 g/dL
    7. Serum creatinine >1.5 mg/dL
    8. Serum or Aspartate aminotransferase (AST) > 250 IU/L at Visit 1 or Visit 2 .
  18. to Saroglitazar Magnesium or has any conditions affecting the ability to evaluate the effects of Saroglitazar Magnesium.
  19. Known allergy, sensitivity or intolerance to the study drug, placebo or formulation ingredients.
  20. Participation in any other therapeutic clinical study within the 3 months preceding Visit 1, including participation in any other NAFLD/NASH clinical trials.
  21. History of bladder disease and/or hematuria or has current hematuria except due to a urinary tract infection.
  22. Illicit substance abuse within the 12 months preceding Visit 1.
  23. Pregnancy-related exclusions, including:

    1. Pregnant/lactating female (including a positive serum pregnancy test at Visit 1)
    2. A male patient has to use a condom with spermicide, and the female partner of the male patient has to use an intrauterine device OR a diaphragm with spermicide OR oral contraceptive pills.
    3. If a male patient has undergone a vasectomy, the female partner does not have to use any contraception.
    4. A female patient has to use either an intrauterine device OR a diaphragm with spermicide OR oral contraceptive pills. The male partner of the female patient has to use a condom with spermicide.
    5. If the female patient is surgically sterilized for at least the 6 months preceding Visit 1 or , defined as at least 12 months with no menses and without an alternative cause, the male partner of the female patient does not have to use any contraception.
  24. History or other evidence of severe illness or any other conditions that would make the patient, in the opinion of the investigator, unsuitable for the study (such as poorly controlled psychiatric disease, , coronary artery disease or active gastrointestinal conditions that might interfere with drug absorption).
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    Saroglitazar magnesium 1 mg

    Saroglitazar magnesium 1 mg tablet orally once daily in the morning before breakfast for 16 weeks.

    Drug: Saroglitazar magnesium 1 mg

  • Experimental
    Saroglitazar magnesium 2 mg

    Saroglitazar magnesium 2 mg tablet orally once daily in the morning before breakfast for 16 weeks.

    Drug: Saroglitazar magnesium 2 mg

  • Experimental
    Saroglitazar magnesium 4 mg

    Saroglitazar magnesium 4 mg tablet orally once daily in the morning before breakfast for 16 weeks.

    Drug: Saroglitazar magnesium 4 mg

  • Placebo comparator
    Placebos

    Placebo tablet orally once daily in the morning before breakfast for 16 weeks.

    Drug: Placebos

Interventions

  • Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.

  • Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.

  • Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.

  • DrugPlacebos

    Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage Change From Baseline in Serum Alanine Aminotransferase (ALT) Levels at Week 16

    Percentage change from baseline in serum ALT levels at Week 16 in the Saroglitazar Magnesium groups as compared to the placebo group

    Time frame: Baseline and Week 16

Secondary outcomes

  1. Change in Liver Fat Content as Measured by Magnetic Resonance Imaging-derived Proton Density-fat Fraction (MRI-PDFF)

    Change in liver fat content as measured by magnetic resonance imaging-derived proton in Saroglitazar Magnesium groups as compared to the placebo group

    Time frame: Baseline and Week 16

  2. Proportion of Patients With Sustain Decrease in Serum ALT Levels

    Proportion of patients with sustain decrease in serum ALT levels in Saroglitazar Magnesium groups as compared to the placebo group

    Time frame: Week 16

  3. Changes in Cytokeratin-18

    Changes in cytokeratin-18 in Saroglitazar Magnesium groups as compared to the placebo group

    Time frame: baseline and Week 16

  4. Changes in Enhanced Liver Fibrosis

    Changes in enhanced liver fibrosis in Saroglitazar Magnesium groups as compared to the placebo group The ELF Score is a liver fibrosis score that is calculated by use of an algorithm: ELF score score = -7.412 + (ln(HA)\*0.681) + (ln(P3NP)\*0.775) + (ln(TIMP1)\*0.494). HA=hyaluronic acid concentration P3NP=procollagen 3 amino terminal peptide concentration TIMP1=tissue inhibitor matrix metalloproteinase 1 concentration. All are measured in serum. The ELF score has been reported to show good correlations with fibrosis stages in chronic liver disease, with higher ELF scores associated with higher fibrosis stages. The ELF score is hence used as a prognostic marker for disease progression: ELF score \< 9.8 : Low risk of progression, ELF score 9.8 to \< 11.3 : Moderate risk of progression and ELF score \> = 11.3 : High risk of progression

    Time frame: baseline and Week 16

  5. Change in Aspartate Aminotransferase-to-platelet Ratio Index

    Change in aspartate aminotransferase-to-platelet ratio index in Saroglitazar Magnesium groups as compared to the placebo group APRI was calculated as (\[AST level/AST upper limit of normal\]/ \[Platelet count 1\^09/L\]) ×100, where AST is aspartate aminotransferase. The aspartate transaminase to platelet ratio index (APRI) is used to assess the risk of liver fibrosis. Higher APRI score represents a higher risk of liver fibrosis

    Time frame: Baseline and Week 16

  6. Pharmacokinetics of Saroglitazar Magnesium: Maximum Plasma Concentration (Cmax)

    Maximum plasma concentration (Cmax) of Saroglitazar

    Time frame: PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 7 (Week 16)

  7. Time to Reach Maximum Plasma Concentration (Tmax)

    Time to reach maximum plasma concentration (Tmax) of saroglitazar

    Time frame: PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 7 (Week 16)

  8. Terminal Half-life (t1/2)

    Terminal Half-life (t1/2) of saroglitazar

    Time frame: PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 7 (Week 16)

  9. Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-t)

    Area under the curve from the time of dosing to the last measurable concentration for saroglitazar

    Time frame: PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 3 (Week 0)

  10. Area Under the Curve From the Time of Dosing to the Infinity (AUC 0-inf)

    Area under the curve from the time of dosing to the infinity (AUC 0-inf) for Saroglitazar

    Time frame: PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 3 (Week 0)

  11. Elimination Rate Constant (λz)

    Elimination rate constant (λz) for saroglitazar

    Time frame: PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 7 (Week 16)

  12. Apparent Volume of Distribution (Vd/F)

    Apparent volume of distribution (Vd/F) for Saroglitazar

    Time frame: PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 7 (Week 16)

  13. Apparent Clearance (CL/F)

    Apparent clearance (CL/F) for Saroglitazar

    Time frame: PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 7 (Week 16)

  14. Change in Quality of Life Assessed by the Short-Form 36 Health Survey

    Quality of life will be assessed by the Short-Form 36 Health Survey The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.

    Time frame: baseline and 16 Week

  15. Safety and Tolerability of Saroglitazar Magnesium

    Number of participants with adverse events

    Time frame: Baseline to Week 17

07

Results

Posted Oct 24, 2024

Participant flow

Participant flow — Overall Study
MilestoneSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebos
Started26252728
Completed26202725
Not completed0503

Outcome measures

PrimaryPercentage Change From Baseline in Serum Alanine Aminotransferase (ALT) Levels at Week 16

Percentage change from baseline in serum ALT levels at Week 16 in the Saroglitazar Magnesium groups as compared to the placebo group

Time frame:
Baseline and Week 16
Reported as:
Mean · Percentage change
Percentage Change From Baseline in Serum Alanine Aminotransferase (ALT) Levels at Week 16
Percentage changeSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Percentage Change From Baseline in Serum Alanine Aminotransferase (ALT) Levels at Week 16-26.2 ± 33.36-27.0 ± 26.52-44.9 ± 26.262.6 ± 32.06
Statistical analysis
  • Saroglitazar Magnesium 1 mg vs Placebo · ANCOVA · p = 0.0002
  • Saroglitazar Magnesium 2 mg vs Placebo · ANCOVA · p = 0.0001
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = <0.0001
SecondaryChange in Liver Fat Content as Measured by Magnetic Resonance Imaging-derived Proton Density-fat Fraction (MRI-PDFF)

Change in liver fat content as measured by magnetic resonance imaging-derived proton in Saroglitazar Magnesium groups as compared to the placebo group

Time frame:
Baseline and Week 16
Reported as:
Mean · percentage of Liver fat
Change in Liver Fat Content as Measured by Magnetic Resonance Imaging-derived Proton Density-fat Fraction (MRI-PDFF)
percentage of Liver fatSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Change in Liver Fat Content as Measured by Magnetic Resonance Imaging-derived Proton Density-fat Fraction (MRI-PDFF)0.53 ± 5.228-0.36 ± 4.297-4.21 ± 6.231-0.28 ± 5.409
Statistical analysis
  • Saroglitazar Magnesium 1 mg vs Placebo · ANCOVA · p = 0.5681
  • Saroglitazar Magnesium 2 mg vs Placebo · ANCOVA · p = 0.4487
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0021
SecondaryProportion of Patients With Sustain Decrease in Serum ALT Levels

Proportion of patients with sustain decrease in serum ALT levels in Saroglitazar Magnesium groups as compared to the placebo group

Time frame:
Week 16
Reported as:
Count of participants · Participants
Proportion of Patients With Sustain Decrease in Serum ALT Levels
ParticipantsSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Proportion of Patients With Sustain Decrease in Serum ALT Levels22222614
Statistical analysis
  • Saroglitazar Magnesium 1 mg vs Placebo · Chi-squared · p = 0.0070
  • Saroglitazar Magnesium 2 mg vs Placebo · Chi-squared · p = 0.0031
  • Saroglitazar Magnesium 4 mg vs Placebo · Chi-squared · p = 0.0001
SecondaryChanges in Cytokeratin-18

Changes in cytokeratin-18 in Saroglitazar Magnesium groups as compared to the placebo group

Time frame:
baseline and Week 16
Reported as:
Mean · U/L
Changes in Cytokeratin-18
U/LSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Changes in Cytokeratin-18-3.0 ± 693.75-330.3 ± 590.37-64.1 ± 303.5997.4 ± 437.10
Statistical analysis
  • Saroglitazar Magnesium 1 mg vs Placebo · ANCOVA · p = 0.2241
  • Saroglitazar Magnesium 2 mg vs Placebo · ANCOVA · p = 0.0304
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0595
SecondaryChanges in Enhanced Liver Fibrosis

Changes in enhanced liver fibrosis in Saroglitazar Magnesium groups as compared to the placebo group The ELF Score is a liver fibrosis score that is calculated by use of an algorithm: ELF score score = -7.412 + (ln(HA)\*0.681) + (ln(P3NP)\*0.775) + (ln(TIMP1)\*0.494). HA=hyaluronic acid concentration P3NP=procollagen 3 amino terminal peptide concentration TIMP1=tissue inhibitor matrix metalloproteinase 1 concentration. All are measured in serum. The ELF score has been reported to show good correlations with fibrosis stages in chronic liver disease, with higher ELF scores associated with higher fibrosis stages. The ELF score is hence used as a prognostic marker for disease progression: ELF score \< 9.8 : Low risk of progression, ELF score 9.8 to \< 11.3 : Moderate risk of progression and ELF score \> = 11.3 : High risk of progression

Time frame:
baseline and Week 16
Reported as:
Mean · units on a scale
Changes in Enhanced Liver Fibrosis
units on a scaleSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Changes in Enhanced Liver Fibrosis-0.2 ± 0.78-0.3 ± 0.86-0.3 ± 0.720.4 ± 0.78
Statistical analysis
  • Saroglitazar Magnesium 1 mg vs Placebo · ANCOVA · p = 0.0449
  • Saroglitazar Magnesium 2 mg vs Placebo · ANCOVA · p = 0.0053
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0036
SecondaryChange in Aspartate Aminotransferase-to-platelet Ratio Index

Change in aspartate aminotransferase-to-platelet ratio index in Saroglitazar Magnesium groups as compared to the placebo group APRI was calculated as (\[AST level/AST upper limit of normal\]/ \[Platelet count 1\^09/L\]) ×100, where AST is aspartate aminotransferase. The aspartate transaminase to platelet ratio index (APRI) is used to assess the risk of liver fibrosis. Higher APRI score represents a higher risk of liver fibrosis

Time frame:
Baseline and Week 16
Reported as:
Mean · units on a scale
Change in Aspartate Aminotransferase-to-platelet Ratio Index
units on a scaleSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Change in Aspartate Aminotransferase-to-platelet Ratio Index-0.3 ± 0.56-0.2 ± 0.51-0.3 ± 0.470.1 ± 0.73
Statistical analysis
  • Saroglitazar Magnesium 1 mg vs Placebo · ANCOVA · p = 0.0045
  • Saroglitazar Magnesium 2 mg vs Placebo · ANCOVA · p = 0.0026
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0004
SecondaryPharmacokinetics of Saroglitazar Magnesium: Maximum Plasma Concentration (Cmax)

Maximum plasma concentration (Cmax) of Saroglitazar

Time frame:
PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 7 (Week 16)
Reported as:
Mean · ng/mL
Pharmacokinetics of Saroglitazar Magnesium: Maximum Plasma Concentration (Cmax)
ng/mLSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mg
Pharmacokinetics of Saroglitazar Magnesium: Maximum Plasma Concentration (Cmax)65.034 ± 17.57998.995 ± 77.189219.475 ± 111.521
SecondaryTime to Reach Maximum Plasma Concentration (Tmax)

Time to reach maximum plasma concentration (Tmax) of saroglitazar

Time frame:
PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 7 (Week 16)
Reported as:
Median · hours
Time to Reach Maximum Plasma Concentration (Tmax)
hoursSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mg
Time to Reach Maximum Plasma Concentration (Tmax)0.920 (0.500 to 1.020)1.500 (1.000 to 3.000)0.990 (0.500 to 2.080)
SecondaryTerminal Half-life (t1/2)

Terminal Half-life (t1/2) of saroglitazar

Time frame:
PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 7 (Week 16)
Reported as:
Mean · hour
Terminal Half-life (t1/2)
hourSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mg
Terminal Half-life (t1/2)6.040 ± 1.3146.597 ± 4.2175.429 ± 1.509
SecondaryArea Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-t)

Area under the curve from the time of dosing to the last measurable concentration for saroglitazar

Time frame:
PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 3 (Week 0)
Reported as:
Mean · hr*ng/mL
Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-t)
hr*ng/mLSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mg
Area Under the Curve From the Time of Dosing to the Last Measurable Concentration (AUC0-t)171.064 ± 45.818301.227 ± 202.061667.646 ± 175.024
SecondaryArea Under the Curve From the Time of Dosing to the Infinity (AUC 0-inf)

Area under the curve from the time of dosing to the infinity (AUC 0-inf) for Saroglitazar

Time frame:
PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 3 (Week 0)
Reported as:
Mean · hr*ng/mL
Area Under the Curve From the Time of Dosing to the Infinity (AUC 0-inf)
hr*ng/mLSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mg
Area Under the Curve From the Time of Dosing to the Infinity (AUC 0-inf)167.735 ± 45.322305.532 ± 203.074652.497 ± 169.565
SecondaryElimination Rate Constant (λz)

Elimination rate constant (λz) for saroglitazar

Time frame:
PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 7 (Week 16)
Reported as:
Mean · per hour
Elimination Rate Constant (λz)
per hourSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mg
Elimination Rate Constant (λz)0.119 ± 0.0270.129 ± 0.0470.136 ± 0.035
SecondaryApparent Volume of Distribution (Vd/F)

Apparent volume of distribution (Vd/F) for Saroglitazar

Time frame:
PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 7 (Week 16)
Reported as:
Mean · mL
Apparent Volume of Distribution (Vd/F)
mLSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mg
Apparent Volume of Distribution (Vd/F)49788.200 ± 18040.18881341.167 ± 72030.40653772.143 ± 17575.770
SecondaryApparent Clearance (CL/F)

Apparent clearance (CL/F) for Saroglitazar

Time frame:
PK sampling timepoints: Pre-dose (0.0), 0.5, 1.0, 2.0, 3.0, 4.0, 6.0, 8.0, 10.0, and 24 hours post-dose of Visit 7 (Week 16)
Reported as:
Mean · mL/hour
Apparent Clearance (CL/F)
mL/hourSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mg
Apparent Clearance (CL/F)5969.472 ± 2502.3138030.060 ± 2356.6206972.059 ± 1890.090
SecondaryChange in Quality of Life Assessed by the Short-Form 36 Health Survey

Quality of life will be assessed by the Short-Form 36 Health Survey The SF-36 is a multi-purpose, short-form health survey with 36 questions. It yields an 8-scale profile of functional health and well-being scores (domains) as well as psychometrically based physical and mental health summary measures. The SF-36 taps 8 health concepts: physical functioning, bodily pain, physical role functioning, emotional role functioning, emotional well-being, social functioning, vitality, and general health perceptions. The 8 scales are further summarized to 2 distinct higher-ordered clusters: the PCS and mental composite t-score (MCS). The range for all 8 domains as well as for the composite t-scores is from 0 to 100 with 100 as best possible health status and 0 as worst health status.

Time frame:
baseline and 16 Week
Reported as:
Mean · units on a scale
Change in Quality of Life Assessed by the Short-Form 36 Health Survey
units on a scaleSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebo
Change in Quality of Life Assessed by the Short-Form 36 Health Survey-1.7 ± 7.24-2.2 ± 7.57-3.8 ± 10.77-1.0 ± 6.16
Statistical analysis
  • Saroglitazar Magnesium 1 mg vs Placebo · ANCOVA · p = 0.2387
  • Saroglitazar Magnesium 2 mg vs Placebo · ANCOVA · p = 0.1496
  • Saroglitazar Magnesium 4 mg vs Placebo · ANCOVA · p = 0.0445
SecondarySafety and Tolerability of Saroglitazar Magnesium

Number of participants with adverse events

Time frame:
Baseline to Week 17
Reported as:
Number · participants
Safety and Tolerability of Saroglitazar Magnesium
participantsSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebos
Safety and Tolerability of Saroglitazar Magnesium13131419

Adverse events

Collected over 16 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Saroglitazar Magnesium 1 mg0/26 (0%)1/26 (3.8%)7/26 (26.9%)
Saroglitazar Magnesium 2 mg0/25 (0%)0/25 (0%)6/25 (24%)
Saroglitazar Magnesium 4 mg0/27 (0%)1/27 (3.7%)3/27 (11.1%)
Placebos0/28 (0%)0/28 (0%)5/28 (17.9%)
Most frequent serious events
Most frequent serious events
EventSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebos
UreterolithiasisRenal and urinary disorders1/260/250/270/28
Mental Status ChangePsychiatric disorders0/260/251/270/28
Most frequent other events
Most frequent other events
EventSaroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebos
HeadacheNervous system disorders3/261/251/270/28
AnemiaBlood and lymphatic system disorders0/262/250/270/28
Abdominal painGastrointestinal disorders0/262/250/270/28
Upper respiratory tract infectionInfections and infestations1/262/252/270/28
DiarrhoeaGastrointestinal disorders2/261/250/271/28
CoughRespiratory, thoracic and mediastinal disorders2/260/251/270/28
Urinary tract infectionInfections and infestations0/260/251/272/28
HaematuriaRenal and urinary disorders1/260/251/272/28
FlatulenceGastrointestinal disorders0/260/250/272/28

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Saroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebosTotal
Mean51.1 ± 12.8947.9 ± 10.4449 ± 10.9748.7 ± 10.4649.2 ± 11.13
Sex: Female, Male
Sex: Female, Male(Participants)Saroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebosTotal
Female1312121350
Male1313151556
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Saroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebosTotal
Hispanic or Latino108121343
Not Hispanic or Latino1617151563
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Saroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebosTotal
American Indian or Alaska Native10001
Asian333312
Native Hawaiian or Other Pacific Islander00000
Black or African American00000
White2221242491
More than one race00000
Unknown or Not Reported01012
Body Mass Index
Body Mass Index(kg/m^2)Saroglitazar Magnesium 1 mgSaroglitazar Magnesium 2 mgSaroglitazar Magnesium 4 mgPlacebosTotal
Mean33.630 ± 4.245135.702 ± 8.565332.489 ± 5.161133.809 ± 4.459933.875 ± 5.8374
08

Study locations

18 sites
  • Precision Research
    Chula Vista, California 91910, United States
  • Cedars-Sinai Medical Center
    Los Angeles, California 90048, United States
  • Catalina Research Institute
    Montclair, California 91763, United States
  • California liver research institute
    Pasadena, California 91105, United States
  • Precision Research
    San Diego, California 92114, United States
  • University of Florida
    Gainesville, Florida 32601, United States
  • Schiff Center for Liver Diseases/University of Miami
    Miami, Florida 33136, United States
  • Avail Clinical Research
    Orange City, Florida 32763, United States
  • Indiana University
    Indianapolis, Indiana 46290, United States
  • Mercy Medical Center
    Baltimore, Maryland 21201, United States
  • University of Michigan
    Ann Arbor, Michigan 48109-5362, United States
  • Awasty Research Network, LLC
    Marion, Ohio 43302, United States
  • Einstein Medical Center
    Philadelphia, Pennsylvania 19141, United States
  • Gastro One
    Germantown, Tennessee 38138, United States
  • AIG Research
    Hermitage, Tennessee 37076, United States
  • Liver Consultants
    Dallas, Texas 75246, United States
  • The Liver Institute
    San Antonio, Texas 78215, United States
  • Swedish Medical Center
    Seattle, Washington 89104, United States
09

References and documents

Publications

  • Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, Charlton M, Sanyal AJ. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012 Jun;55(6):2005-23. doi: 10.1002/hep.25762. No abstract available. PubMed 22488764 ↗
  • Gawrieh S, Noureddin M, Loo N, Mohseni R, Awasty V, Cusi K, Kowdley KV, Lai M, Schiff E, Parmar D, Patel P, Chalasani N. Saroglitazar, a PPAR-alpha/gamma Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial. Hepatology. 2021 Oct;74(4):1809-1824. doi: 10.1002/hep.31843. Epub 2021 Jul 19. PubMed 33811367 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2017 to primary completion in Aug 2019, 28 months.

Results were first posted in Oct 2024, 5 years 2 months after primary completion.

Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 28 months is above that.

Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 7, 2017
First posted
Feb 23, 2017
StartActual
Apr 6, 2017
Primary completionActual
Aug 22, 2019
CompletionActual
Aug 22, 2019
Results first posted
Oct 24, 2024
Last update
Oct 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03061721
Responsible party
Sponsor
First posted
Feb 23, 2017
Start date
Apr 6, 2017
Primary completion
Aug 22, 2019
Completion
Aug 22, 2019
Results posted
Oct 24, 2024
Last update
Oct 24, 2024

Study contacts

Deven V Parmar, MD,FACP,FCP
study director · Zydus Therapeutics Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Saroglitazar

Start the discussion